Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a year. I think now is a terrific opportunity to scoop up shares of Novo on the ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Ozempic's ads were 57% more effective in driving consumer engagement on streaming TV than on linear TV during Q3.

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Analysts at Intron Health, led by Naresh Chouhan, suggested that Friday's market reaction was excessively severe.

Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

The blockbuster drug, launched in the US a couple of years ago, is forecasted to reach global sales of $27 billion by 2029, overtaking Novo Nordisk‘s Ozempic (semaglutide) in the same weight loss ...